Skip to main content
MBX Biosciences, Inc. logo

MBX Biosciences, Inc. — Investor Relations & Filings

Ticker · MBX ISIN · US55287L1017 US Manufacturing
Open in API
Filings indexed 168 across all filing types
Latest filing 2026-06-05 Declaration of Voting R…
Country US United States of America
Listing US MBX

About MBX Biosciences, Inc.

https://mbxbio.com/

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for endocrine and metabolic diseases. The company is pioneering a proprietary platform of investigational Precision Endocrine Peptides (PEPs)™. This technology is designed to create highly specific and potent peptide therapeutics that address the underlying mechanisms of disease. MBX's pipeline targets rare and underserved endocrine disorders, such as hypoparathyroidism, with the goal of developing transformative, best-in-class medicines that simplify disease management and improve patients' quality of life.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report disclosing the results of shareholder votes at the Company’s 2026 Annual Meeting, including election of Class II directors and ratification of the independent auditor. This constitutes an official declaration of voting results from a general meeting, matching the "Declaration of Voting Results & Voting Rights Announcements" category.
2026-06-05 English
8-K - MBX Biosciences, Inc. (0001776111) (Filer)
Regulatory Filings Classification · 90% confidence The document is a U.S. SEC Form 8-K “Current Report” covering Regulation FD disclosure and other corporate updates, including furnished exhibits (press release and corporate presentation). It is a routine regulatory filing rather than an earnings release, investor presentation itself, or financial report. It does not represent a full annual/quarterly report, proxy, or capital action. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-11 English
8-K - MBX Biosciences, Inc. (0001776111) (Filer)
Earnings Release Classification · 90% confidence The document is a Form 8-K Current Report filed under Item 2.02 “Results of Operations and Financial Condition,” which furnishes a press release announcing the company’s quarterly financial results for the period ended March 31, 2026. This matches the definition of an Earnings Release (ER): an initial announcement of periodic financial results. Q1 2026
2026-05-07 English
10-Q - MBX Biosciences, Inc. (0001776111) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
ARS - MBX Biosciences, Inc. (0001776111) (Filer)
Annual Report
2026-04-22 English
DEF 14A - MBX Biosciences, Inc. (0001776111) (Filer)
Proxy Solicitation & Information Statement
2026-04-22 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.